Search

Displaying results 2101 - 2110 of 6831 in total
  1. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia® … It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.

  2. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    , and are switched to camizestrant while continuing the same CDK4/6 inhibitor. … Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally

  3. Drug

    Fludrocortisone

    go.drugbank.com/drugs/DB00687
    ApprovedInvestigational

    [A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position … of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.

  4. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    It was approved by the FDA after being given the status of priority review for on July 7, 2015. … Inhibition of neprilysin therefore leads to reduced breakdown and increased concentration of endogenous natriuretic peptides in addition to increased levels of vasoconstricting hormones such as angiotensin

  5. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    [L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma … [A216153, A216158] More recently, chimeric antigen receptor (CAR) T cell therapies have been developed that modify a patient's own T cells using viral transduction to bind to and destroy cancerous cells

    Categories: Receptors, Antigen, T-Cell, CD19-Directed Genetically Modified Autologous T-cell Immunotherapies
  6. Drug

    Glutamic acid

    go.drugbank.com/drugs/DB00142
    ApprovedInvestigationalNutraceutical

    A peptide that is a homopolymer of glutamic acid.

  7. Drug

    Probucol

    go.drugbank.com/drugs/DB01599
    ApprovedInvestigationalWithdrawn

    A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).

  8. Drug

    Bentoquatam

    go.drugbank.com/drugs/DB00516
    Approved

    Bentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak.

  9. Drug

    Filgotinib

    go.drugbank.com/drugs/DB14845
    ApprovedInvestigational

    [A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616] … [A189165] JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity for JAK1 aims to improve the safety profile of filgotinib while maintaining clinical efficacy

  10. Drug

    Homatropine

    go.drugbank.com/drugs/DB11181
    Approved

    use has not been approved by the FDA to be safe and effective. … Homatropine hydrobromide has been administered as ophthalmic solutions as a cycloplegic to temporarily paralyze accomodation, and to induce mydriasis (the dilation of the pupil); however such therapeutic